8th Dec 2006 14:00
PuriCore Plc08 December 2006 PuriCore's Greg Bosch wins 'Life Sciences CEO of the year' award MALVERN, PENNSYLVANIA, and STAFFORD, UK, December 8, 2006 -- PuriCore plc("PuriCore" or the "Company") (London Stock Exchange: PURI) today announces thatits CEO, Greg Bosch, has been awarded the 'Life Sciences CEO of the Year' awardat the annual Eastern Technology Council's ("ETC") Enterprise Awards inPhiladelphia. Over the past 14 years, the ETC Awards have developed the reputation as beingone of the most prestigious honours for a company to win on the East Coast ofthe United States. Bosch was appointed CEO of PuriCore in November 2004 and has been instrumentalin the commercialisation of PuriCore's proprietary technology, known asSterilox. In June 2006, Greg led the Company through a successful flotation onthe London Stock Exchange, raising £30 million ($54.5 million). Greg Bosch commented: "I am honoured to receive this award. It reflects thehard work and dedication of the entire team at PuriCore as we continue towardsour vision to be a global leader in advancing human health through theenvironmental control of pathogens." FOR FURTHER INFORMATION: PuriCore plc Tel: +1 (484) 321 2701Greg Bosch, Chief Executive OfficerKeith A. Goldan, Chief Financial Officer Financial Dynamics Tel: +44 (0) 20 7831 3113Ben BrewertonJohn Gilbert ABOUT PURICORE PLC PuriCore is a life sciences company focused on the development andcommercialisation of its proprietary technology that mimics the production bythe human body of its natural anti-microbial, hypochlorous acid. Hypochlorousacid is highly effective at killing pathogens such as bacteria, viruses andfungi and yet is safe and environmentally friendly. PuriCore's solutions haveapplications in a wide range of markets where it is important to controlmicrobial contamination. These markets include medical device disinfection,food safety, dental equipment decontamination, environmental remediation,hospitality, water safety, wound management and other applications intended tolimit the spread of infectious disease, including major global disease threatssuch as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, HepatitisA, H.pylori and Legionella. PuriCore markets a portfolio of branded systems which produce hypochlorous acidsolutions on-site at a customer's location from water, electricity and commonsalt. These solutions are generated at a range of concentrations and at anearly neutral pH range similar to the human body. They are effective as soaks,sprays, mists and in other forms. PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford,UK. To receive additional information on the Company, please visit our Web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
RLM.L